---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-016447"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T19:22:25.271219+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vaxart Q1 net loss $15.6M; COVID-19 Phase 2b screening underway, CFO appointed

## Summary
- Net loss $15.6M ($0.07/shr) vs $24.4M ($0.14) prior year; revenue $20.9M from BARDA contract (vs $2.2M).
- Cash $41.9M; runway into Q1 2026; Project NextGen award up to $460.7M, $85.6M received to date.
- Screening for 10,000-person COVID-19 Phase 2b trial started; dosing expected Q2 2025 after stop work order lifted.
- Norovirus Phase 1 enrollment complete (60 participants); topline data mid-2025; avian flu vaccine 100% protective in ferret model.
- Jeroen Grasman appointed CFO effective May 19, 2025; Phillip Lee resigning as CFO for personal reasons.

## SEC filing metadata
- accession: 0001437749-25-016447
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774925016447/0001437749-25-016447-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774925016447/vxrt20250123_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-016447
- JSON: https://secwatch.observer/filing/0001437749-25-016447.json
- Plain text: https://secwatch.observer/filing/0001437749-25-016447.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.